![]() ![]() platform through eight established, reputable, efficiently operating and revenue-producing clinics," says Payton Nyquvest, Founder and CEO, Numinus. The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong U.S. "Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. ("Novamind") (CSE:NM)(OTCQB:NVMDF)(FSE:HN2), are pleased to announce that they have entered into a definitive arrangement agreement (the "Agreement") pursuant to which Numinus will acquire all of the issued and outstanding common shares of Novamind (the "Novamind Shares") in an all-share transaction, by way of a court-approved plan of arrangement, for total consideration of approximately C$26.2 million on a fully diluted in-the-money basis (the "Transaction").įollowing the Transaction, the combined company will operate 13 wellness clinics and will be positioned as a leading psychedelic-assisted therapy provider in North America, leading its peer group in revenue with approximately C$10 million in annual pro-forma revenue based on the trailing four quarters. ("Numinus", the "Company") (TSX:NUMI)(OTCQX:NUMIF) and Novamind Inc. VANCOUVER, BC and TORONTO, ON / ACCESSWIRE / Ap/ Numinus Wellness Inc. Transaction expected to close in June 2022, following anticipated shareholder approval.Acquisition is expected to generate C$3 million in annual cost synergies.Combined C$10 million in annual pro-forma revenue based on the trailing four quarters.Hosting clinical trials for MDMA (MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah).Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare.Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory.Special thanks to our Program Director Shea Gunther. This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications. Links to the guest’s company and social media accounts ![]() Previously, he served in senior investment banking roles at Desjardins Securities and Sandfire Securities, and in CEO, CFO and corporate director roles for private and public companies. He’s an entrepreneur and the principal of Emmcap Corp., an investor in venture-stage companies. Yaron Conforti is the Chief Executive Officer and Director of Novamind. Yaron Conforti, Chief Executive Officer of Novamind So don’t sit back, lean forward and enjoy! As psychedelic investors look for opportunities, they won’t want to miss this interview with Yaron as he delves into how his company is focused on execution and bringing these next-generation treatments to the masses. ![]() Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine.Īs the psychedelic renaissance continues to take shape, our hosts Anne and Nick sat down with Yaron to chat with him about the more than 4,000 ketamine-assisted psychotherapy treatments Novamind has administered, the Company’s expansion plans beyond its home base of Utah and Novamind’s RTO onto the CSE. ![]() Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Yaron Conforti, CEO and Director of Novamind Ventures (CSE: NM), which delivers psychedelic therapies to patients suffering from treatment resistant psychological conditions at its Cedar Psychiatry clinics in Utah, is this week’s special guest on The Green Rush. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |